Navigation Links
Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal

CRANBURY, N.J., June 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications, announced presentation and publication of a report on validation of a scale for subjective male sexual arousal.  The underlying study was supported by grants from Palatin.

Michael A. Perelman, Ph.D., of the New York Presbyterian Hospital and the Weill Medical College of Cornell University, presented the poster on June 13, 2011 at the 20th World Congress for Sexual Health in Glasgow, United Kingdom.  The paper, entitled "The Subjective Sexual Arousal Scale for Men (SSASM): Preliminary Development and Psychometric Validation of a Multidimensional Measure of Subjective Male Sexual Arousal," has been published in the online version of the Journal of Sexual Medicine and will appear in a forthcoming print issue. Stanley E. Althof, Ph.D., Executive Director of the Center for Marital and Sexual Health of South Florida and Emeritus Professor, Case Western Reserve University School of Medicine, and Raymond C. Rosen, Ph.D., of New England Research Institutes, are co-authors on the paper with Dr. Perelman.

The presentation and paper describe development and psychometric validation of a self-administered scale for assessing subjective male sexual arousal.  Based upon recommendations of the Food and Drug Administration guidance on patient-reported outcome instruments, important aspects of male sexual arousal were identified through qualitative research of U.S. men with erectile dysfunction and healthy controls.

The Subjective Sexual Arousal Scale for Men (SSASM) may be useful in drug development for treatment of erectile dysfunction.  The SSASM is the first validated research instrument with a focus on assessing subjective male sexual arousal in men with erectile dysfunction in a clinical trial setting.

Palatin supported the underlying research efforts as part of its commitment to developing novel drugs for treating sexual dysfunction, including both female sexual dysfunction and male erectile dysfunction.

About Bremelanotide

Palatin Technologies, Inc. is developing subcutaneously administered bremelanotide for the treatment of female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies.  An at-home Phase 2 clinical trial of subcutaneously administered bremelanotide for pre-menopausal women with female sexual dysfunction is scheduled to start in the current calendar quarter.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
2. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
3. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
4. Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
5. Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
6. Palatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
7. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
9. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
10. Palatin Announces Strategic Realignment of Operations
11. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):